贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效  

Clinical Efficacy of Bevacizumab Combined with Cisplatin in the Treatment of Malignant Pleural Effusion of Lung Cancer

作　　者：崔晓旭 CUI Xiao-xu(Tonghua Central Hospital,Tonghua,Jilin 134000)

机构地区：[1]吉林省通化市中心医院

出　　处：《智慧健康》2019年第17期139-140,共2页Smart Healthcare

摘　　要：目的研究贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效。方法选择20例肺癌恶性胸水患者作为研究对象,随机分为对照组和研究组,各10例。对照组患者采用顺铂治疗,研究组患者采用贝伐珠单抗联合顺铂治疗,比较两组患者的治疗有效率和不良反应发生率。结果研究组患者的治疗有效率明显优于对照组患者,差异显著,有统计学意义(P<0.05)。两组患者的不良反应发生率差异不显著,无统计学意义(P>0.05)。结论对于肺癌恶性胸水患者采用贝伐珠单抗联合顺铂治疗,能够取得比较好的治疗效果,提升了治疗有效率,患者发生不良反应的情况少。Objective To study the clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion of lung cancer.Methods Twenty patients with malignant pleural effusion of lung cancer admitted to our hospital were randomly divided into the control group and the study group,10 cases each.Patients in the control group were treated with cisplatin.Patients in the study group were treated with bevacizumab plus cisplatin.The treatment efficiency and adverse reaction rate were compared between the two groups.Results The treatment efficiency of the study group was significantly better than that of the control group,and the difference was statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion For patients with malignant pleural effusion of lung cancer,bevacizumab combined with cisplatin can achieve better therapeutic effect,improve the efficiency of treatment,and have fewer adverse reactions in patients.

关 键 词：肺癌恶性胸水 顺铂 贝伐珠单抗 

分 类 号：R734.2[医药卫生—肿瘤]